Deepak Bhamidipati, MD, discusses a review conducted to investigate how the design of early-phase clinical trials has evolved.
Deepak Bhamidipati, MD
Deepak Bhamidipati, MD, is an assistant director of drug development at Sarah Cannon Research Institute.
Articles by Deepak Bhamidipati, MD
Deepak Bhamidipati, MD, discusses the impact of the FDA's Project Optimus on early-phase drug development protocols.